Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis in covid-19 patients with type 2 diabetes.
HIV/AIDS relief efforts disrupted, affecting vulnerable populations with HIV infection, according to PEPFAR findings and survey results.
A new COVID-19 antibody treatment, VYD2311, enters phase 3 trials to evaluate safety and efficacy against mRNA vaccines.